Brain & Spinal Cord Cancer Market by Tumor Type, Treatment, End-users

Description

List of Tables

[187 Pages Report] The Brain & Spinal Cord Cancer Market size was estimated at USD 3.77 billion in 2023 and expected to reach USD 3.98 billion in 2024, at a CAGR 5.75% to reach USD 5.59 billion by 2030.

Brain and spinal cord cancers are types of central nervous system cancers that occur when malignant (cancer) cells grow in the brain or spinal cord tissue. These cancers can disrupt the vital functions controlled by these areas, including muscle control, sensation, memory, and other cognitive abilities. Treatment plans for brain and spinal cord cancers are tailored to each individual's specific condition and may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these. This market's applications span across various medical fields, including neuro-oncology, neurosurgery, radiology, and palliative care. End-users are typically healthcare facilities such as hospitals, clinics, and specialized cancer treatment centers, besides patients requiring diagnostic, therapeutic, and supportive care services. Factors influencing the need for brain and spinal cord cancer treatment include advancements in medical technology, rising prevalence of brain and spinal cord cancers, increased investment in healthcare infrastructure, and awareness about these conditions. However, the market faces certain challenges, such as high treatment costs, limited accessibility to advanced healthcare facilities, and concerns associated with the complex nature of brain and spinal cord cancers. On the other hand, the incorporation of AI and machine learning in diagnostic processes and increasing preference for personalized medicine based on genetic profile present potential opportunities for the brain and spinal cord cancers market.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.77 billion
Estimated Year [2024]	USD 3.98 billion
Forecast Year [2030]	USD 5.59 billion
CAGR (%)	5.75%

Treatment:

Diagnosis forms the cornerstone of cancer treatment, with accurate identification pivotal for effective management strategies. For brain and spinal cord cancers, diagnosis primarily involves imaging techniques and biopsy procedures. Advanced imaging methods, including CT scans, MRI, and Positron Emission Tomography (PET) scans, play a vital role in diagnosing brain and spinal cord cancers. Biopsies, including needle biopsy and open biopsy, are employed to confirm the presence of cancer through tissue sample analysis. The therapy of brain and spinal cord cancers involves a multi-faceted therapeutic approach, including surgery, radiation therapy, chemotherapy, and targeted therapy. Surgery is often the first line of treatment aimed at tumor removal. Another critical treatment modality is radiation therapy, which employs high-energy rays to destroy cancer cells. Chemotherapy utilizes drugs to kill cancer cells and is often used in conjunction with other treatments. Targeted therapy represents a newer class of cancer treatment that specifically targets cancerous cells without harming normal ones. The selection of a therapeutic approach is highly individualized, based on tumor type, stage, and patient health. Surgery and radiation therapy are preferred for localized tumors to remove or decrease tumor size. In contrast, chemotherapy and targeted therapy are beneficial for managing systemic disease or tumors that are inoperable.

End-users:

Ambulatory surgical centers (ASCs) have become increasingly important in the cure of brain and spinal cord cancer, offering patients minimally invasive surgery options with shorter recovery times. These centers are preferred for cases where the patient's condition is stable and the complexity of the surgery is low to moderate. They emphasize cost-effectiveness, patient convenience, and quick discharge. Diagnostic centers play a critical role in the initial stages of diagnosing brain and spinal cord cancer. These facilities are equipped with advanced imaging technologies including MRI, CT scans, and PET scans, vital for accurate diagnosis and treatment planning. Patients and healthcare providers often prefer specialized diagnostic centers for their advanced technology, quick turnaround times, and high-quality imaging services. Hospitals and clinics are the most comprehensive providers for brain and spinal cord cancer patients, offering various services from diagnosis to advanced treatment options, including surgery, radiation therapy, and chemotherapy. They are preferred for their accessibility, multidisciplinary teams, and ability to handle complex cases and emergencies. While all three segments play vital roles in the continuum of care for brain and spinal cord cancer patients, there are distinct differences in their need-based preferences. ASCs are preferred for their efficiency and cost-effectiveness for less complex surgical needs. Diagnostic centers are critical for early and accurate diagnosis, leveraging advanced imaging technologies. Hospitals and clinics, however, offer the broadest range of services, catering to the most complex and emergent cases, and have the advantage of integrated, multidisciplinary care teams.

Regional Insights

In the Americas, particularly in the United States and Canada, significant investments in research and development have been made to advance the treatment of brain and spinal cord cancers. High healthcare expenses and the presence of major healthcare institutions and biotech firms have propelled advanced research initiatives, including precision medicine and novel therapeutics. In South America, Brazil and Argentina are witnessing moderate development in the treatment of the brain and spinal cord cancer market due to rising healthcare expenditure, increasing incidence of cancer, and gradual improvements in healthcare infrastructure. The EU countries boast a robust healthcare infrastructure and several ongoing initiatives for cancer research and early detection. Increased funding from both public and private sectors towards healthcare research has led to significant breakthroughs. Patients in this region benefit from universal healthcare systems, influencing their ability to access advanced treatments. The Middle East and Africa region encounters unique challenges, including variable healthcare infrastructure and accessibility issues. The focus is gradually shifting towards improving healthcare facilities and cancer care centers, with several governments and NGOs playing a pivotal role. The APAC region is witnessing a rapid transformation in the healthcare sector, driven by growing economies such as China, Japan, and India. These countries have seen a surge in healthcare spending and are at the forefront of technological innovation in cancer treatment. Consumer awareness and demand for quality cancer care are high, leading to greater government and private investment in healthcare infrastructure and research initiatives.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Brain & Spinal Cord Cancer Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Brain & Spinal Cord Cancer Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Brain & Spinal Cord Cancer Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bayer AG, bluebird bio, Inc., Bristol Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Eisai Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc, Merck & Co., Inc., Nektar Therapeutics, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Shimadzu Corporation, Siemens Healthineers, Teva Pharmaceutical Industries Ltd., and Y-mAbs Therapeutics A/S.

Market Segmentation & Coverage

This research report categorizes the Brain & Spinal Cord Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

Tumor Type
- Glioblastoma
- Meningioma
- Pituitary Tumors

Treatment
- Diagnosis
  - Cerebral Arteriogram
  - CT Scan
  - EEG
  - Lumbar Puncture
  - Molecular Testing
  - MRI
  - PET-CT Scan
  - Tissue Sampling

Therapeutics
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Targeted Therapy

End-users
- Ambulatory Surgical Centers
- Diagnostic Centers
- Hospital & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Brain & Spinal Cord Cancer Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Brain & Spinal Cord Cancer Market?

3. What are the technology trends and regulatory frameworks in the Brain & Spinal Cord Cancer Market?

4. What is the market share of the leading vendors in the Brain & Spinal Cord Cancer Market?

5. Which modes and strategic moves are suitable for entering the Brain & Spinal Cord Cancer Market?

Product Code: MRR-9E71DF483B96

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of brain and spinal cord cancers globally
  - 5.1.1.2. Increased investment in healthcare infrastructure with growing awareness about these conditions
  - 5.1.1.3. Ongoing government initiatives aimed at cancer research and early detection
- 5.1.2. Restraints
  - 5.1.2.1. High treatment costs and limited accessibility to advanced healthcare facilities for brain and spinal cord cancer
- 5.1.3. Opportunities
  - 5.1.3.1. Incorporation of AI and machine learning in diagnostic processes
  - 5.1.3.2. Increasing preference for personalized medicine based on genetic profile
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with the complex nature of brain and spinal cord cancers
5.2. Market Segmentation Analysis

5.2.1. Treatment:

5.2.2. End-users:

5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Brain & Spinal Cord Cancer Market, by Tumor Type

6.1. Introduction
6.2. Glioblastoma
6.3. Meningioma
6.4. Pituitary Tumors

7. Brain & Spinal Cord Cancer Market, by Treatment

7.1. Introduction
7.2. Diagnosis
7.3. Therapeutics

8. Brain & Spinal Cord Cancer Market, by End-users

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Diagnostic Centers
8.4. Hospital & Clinics

9. Americas Brain & Spinal Cord Cancer Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Brain & Spinal Cord Cancer Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Brain & Spinal Cord Cancer Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Diakonos' brain tumor vaccine receives FDA's orphan drug designation
- 12.3.2. Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio